{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T03:02:55Z","timestamp":1780023775245,"version":"3.53.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,28]]},"DOI":"10.7759\/cureus.109841","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T02:24:36Z","timestamp":1780021476000},"source":"Crossref","is-referenced-by-count":0,"title":["When Checkpoint Inhibition Goes Off Target: A Rare Case of Pembrolizumab-Induced Acalculous Cholecystitis"],"prefix":"10.7759","author":[{"given":"Lan","family":"Huynh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M","family":"Paulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Shaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0604-2","article-title":"Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment","volume":"7","author":"Abu-Sbeih H","year":"2019","unstructured":"Abu-Sbeih H, Tran CN, Ge PS, et al.. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer. 2019, 7:118. 10.1186\/s40425-019-0604-2","journal-title":"J Immunother Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang Y","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, et al.. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019, 5:1008-19. 10.1001\/jamaoncol.2019.0393","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2062-3","article-title":"Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report","volume":"67","author":"Kashima J","year":"2018","unstructured":"Kashima J, Okuma Y, Shimizuguchi R, Chiba K. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother. 2018, 67:61-5. 10.1007\/s00262-017-2062-3","journal-title":"Cancer Immunol Immunother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002361","article-title":"Immune checkpoint inhibitors suppress hepatitis C virus replication in infected patients with solid tumors","volume":"118","author":"Yibirin M","year":"2023","unstructured":"Yibirin M, Mustafayev K, Hosry J, et al.. Immune checkpoint inhibitors suppress hepatitis C virus replication in infected patients with solid tumors. Am J Gastroenterol. 2023, 118:1609-17. 10.14309\/ajg.0000000000002361","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.9012","article-title":"Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy","volume":"35","author":"Santini FC","year":"2017","unstructured":"Santini FC, Rizvi H, Wilkins O, et al.. Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol. 2017, 35:9012. 10.1200\/JCO.2017.35.15_suppl.9012","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies AM","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, et al.. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017, 28:368-76. 10.1093\/annonc\/mdw443","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.007","article-title":"Late-onset cholecystitis with cholangitis after avelumab treatment in non-small cell lung cancer","volume":"13","author":"Cho JH","year":"2018","unstructured":"Cho JH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Late-onset cholecystitis with cholangitis after avelumab treatment in non-small cell lung cancer. J Thorac Oncol. 2018, 13:e34-6. 10.1016\/j.jtho.2017.10.007","journal-title":"J Thorac Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000958196.51273.d7","article-title":"What made the gallbladder angry? A case of ipilimumab and nivolumab induced acute cholecystitis","volume":"118","author":"Ravella B","year":"2023","unstructured":"Ravella B, Pirzada S, Brinkman M, Khaiser A. What made the gallbladder angry? A case of ipilimumab and nivolumab induced acute cholecystitis. Am J Gastroenterol. 2023, 118:1546-7. 10.14309\/01.ajg.0000958196.51273.d7","journal-title":"Am J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/495462-when-checkpoint-inhibition-goes-off-target-a-rare-case-of-pembrolizumab-induced-acalculous-cholecystitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T02:24:37Z","timestamp":1780021477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/495462-when-checkpoint-inhibition-goes-off-target-a-rare-case-of-pembrolizumab-induced-acalculous-cholecystitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.109841","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}